| VIRXSYS CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120046347 | EXPRESSION OF APOAI AND VARIANTS THEREOF USING SPLICEOSOME MEDIATED RNA TRANS-SPLICING - Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analogue of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analogue of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i.e., atherosclerosis, strokes and heart attacks. | 02-23-2012 |
| 20110263015 | COMPOSITIONS AND METHODS FOR GENERATION OF PLURIPOTENT STEM CELLS - The present invention describes the use of pre-trans-splicing molecules (PTMs) to reprogram human normal and diseased somatic cells into pluripotent stem cells using spliceosome-mediated RNA trans-splicing. More specifically, the present invention describes the use of the SMaRT™ technology to repair or reprogram the newly induced diseased pluripotent stem cells. | 10-27-2011 |
| 20110244519 | USE OF RNA TRANS-SPLICING FOR ANTIBODY GENE TRANSFER AND ANTIBODY POLYPEPTIDE PRODUCTION - The present invention provides methods and compositions for generating novel nucleic acid molecules through RNA trans-splicing that target a highly expressed pre-mRNA and contain the coding sequence for antibody polypeptide(s). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with the target precursor messenger RNA molecule (target pre-mRNA) that is abundantly expressed or tumor specific and mediate a trans-splicing reaction resulting in the generation of novel chimeric RNA molecule (chimeric RNA) capable of encoding an antibody polypeptide. The invention provides for the in vivo production of chimeric RNA molecules that encode and result in the production of an antibody polypeptide that is therapeutically effective against, for example, infectious agents, cancer cells, transplantation antigens, rheumatoid arthritis, etc. | 10-06-2011 |
| 20110207226 | NON-INTEGRATING LENTI/ADENO-ASSOCIATED VIRUS HYBRID VECTOR SYSTEM - The present invention provides for a hybrid vector system for the purpose of therapeutic gene delivery where the system is used for a targeted integration of a therapeutic gene into a genome. The hybrid vector system comprises a hybrid vector made up of a non-integrating lentiviral vector and an adeno-associated vector, and a therapeutic gene. | 08-25-2011 |
| 20090203143 | TRANS-SPLICING MEDIATED PHOTODYNAMIC THERAPY - The present invention provides methods and compositions for conferring selective death on cells expressing a specific target precursor messenger RNA (selective target pre-mRNA). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) expressed within a cell and mediate a trans-splicing reaction resulting in the generation of a novel chimeric mRNA molecule (chimeric mRNA) capable of encoding a light producing protein or enzyme. Cell death is further mediated by the presence of a photosensitizer which upon photoactivation produces cytotoxicity. | 08-13-2009 |
| 20090081682 | HIGH-THROUGHPUT METHODS FOR IDENTIFYING GENE FUNCTION USING LENTIVIRAL VECTORS - The present invention relates to methods and compositions for the efficient identification of one or more functionalities of a product encoded by a nucleic acid sequence of interest. The methods utilize the abilities to over and/or under express the product in a cell, as well as the combination of these results, to permit the identification of at least one of the product's cellular or in vivo functionality. | 03-26-2009 |
| 20080274091 | Autologous T Cell Manufacturing Processes - The invention provides novel processes for manufacturing autologous T cells, transducing T cells and expanding the transduced T cell population. | 11-06-2008 |
